Literature DB >> 15750627

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.

Gyorgy Petrovics1, Aijun Liu, Syed Shaheduzzaman, Bungo Furusato, Bungo Furasato, Chen Sun, Yongmei Chen, Martin Nau, Lakshmi Ravindranath, Yidong Chen, Albert Dobi, Vasantha Srikantan, Isabell A Sesterhenn, David G McLeod, Maryanne Vahey, Judd W Moul, Shiv Srivastava.   

Abstract

Transcription factors encoded by the ETS family of genes are central in integrating signals that regulate cell growth and differentiation, stress responses, and tumorigenesis. This study, analysing laser microdissected paired benign and malignant prostate epithelial cells from prostate cancer (CaP) patients (n=114; 228 specimen) by GeneChip and quantitative real-time RT-PCR, identifies ETS-related gene (ERG), a member of the ETS transcription factor family, as the most frequently overexpressed proto-oncogene in the transcriptome of malignant prostate epithelial cells. Combined quantitative expression analysis of ERG with two other genes commonly overexpressed in CaP, AMACR and DD3, revealed overexpression of at least one of these three genes in virtually all CaP specimen (54 of 55). Comprehensive evaluation of quantitative ERG1 expression with clinicopathological features also suggested that ERG1 expression level in prostate tumor cells relative to benign epithelial cells is indicator of disease-free survival after radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750627     DOI: 10.1038/sj.onc.1208518

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  137 in total

1.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.

Authors:  Wendell S Fortson; Shubhalaxmi Kayarthodi; Yasuo Fujimura; Huali Xu; Roland Matthews; William E Grizzle; Veena N Rao; Ganapathy K Bhat; E Shyam P Reddy
Journal:  Int J Oncol       Date:  2011-04-21       Impact factor: 5.650

Review 2.  TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Authors:  Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

3.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Susan Chilton-Macneill; Jane Bayani; Shamini Selvarajah; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

4.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Authors:  Ashish B Rajput; Melinda A Miller; Alessandro De Luca; Niki Boyd; Sam Leung; Antonio Hurtado-Coll; Ladan Fazli; Edward C Jones; Jodie B Palmer; Martin E Gleave; Michael E Cox; David G Huntsman
Journal:  J Clin Pathol       Date:  2007-01-26       Impact factor: 3.411

Review 5.  TMPRSS2-ETS fusion prostate cancer: biological and clinical implications.

Authors:  Francesca Demichelis; Mark A Rubin
Journal:  J Clin Pathol       Date:  2007-11       Impact factor: 3.411

Review 6.  Risk factors for prostate cancer.

Authors:  Amit R Patel; Eric A Klein
Journal:  Nat Clin Pract Urol       Date:  2009-02

Review 7.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status.

Authors:  Liyan Xue; Xueying Mao; Guoping Ren; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Dongmei Lin; Luis Beltran; Daniel M Berney; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 9.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

10.  ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Authors:  J R Gsponer; M Braun; V J Scheble; T Zellweger; A Bachmann; S Perner; T Vlajnic; M Srivastava; S H Tan; A Dobi; I A Sesterhenn; S Srivastava; L Bubendorf; C Ruiz
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-01-28       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.